Fed Circ. Rejects Amgen Bid For DNA Patent
In a decision that raises the bar for biotechnology companies to protect their work on DNA sequencing, Amgen Inc. has lost a federal appeals court fight to obtain a patent related...To view the full article, register now.
Already a subscriber? Click here to view full article